Pharma wants Canberra to get "back to business"
This article was originally published in Scrip
Innovator pharmaceutical companies are calling on Australia's new Labor minority government to get "back to business" and pursue previously agreed measures designed to provide pricing stability as well as speeding up reimbursement decisions on new but expensive drugs through the state-backed Pharmaceutical Benefits Scheme (PBS).
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.